R 343

Drug Profile

R 343

Alternative Names: R-343; R-940343

Latest Information Update: 27 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antiallergics; Antiasthmatics; Diamines; Pyrimidines; Small molecules
  • Mechanism of Action Immunoglobulin inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma

Most Recent Events

  • 26 Aug 2013 Discontinued - Phase-II for Allergic asthma in Canada (Inhalation)
  • 26 Aug 2013 Discontinued - Phase-II for Allergic asthma in USA (Inhalation)
  • 01 Jul 2013 Rigel Pharmaceuticals completes the phase II SITAR trial in Allergic asthma in USA and Canada (NCT01591044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top